Similarly, MYC-amplified spinal cord ependymoma has consistently been shown to have inactivating mutations and loss of heterozygosity of the NF2 gene, which correlates with unfavorable outcomes [20]. The gene discussed is MYC; the disease is spinal cord ependymoma.